Changeflow GovPing Healthcare & Life Sciences TYK2 Inhibitor Compound, BeOne Medicines, US126...
Routine Rule Added Final

TYK2 Inhibitor Compound, BeOne Medicines, US12606556B2

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent US12606556B2 to BeOne Medicines I GmbH on April 21, 2026, covering a TYK2 inhibitor compound (Formula I) and its pharmaceutical uses for treating inflammatory or autoimmune diseases. The patent contains 17 claims and classifies under CPC C07D 471/04. Inventors are Qiuwen Wang, Yunhang Guo, and Zhiwei Wang. The patent creates intellectual property rights but does not impose compliance obligations on third parties.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued Patent US12606556B2 to BeOne Medicines I GmbH covering a TYK2 inhibitor compound of Formula (I), methods of using the compound to inhibit TYK2, and methods of treating TYK2-related inflammatory or autoimmune diseases. The patent includes 17 claims and classifies under C07D 471/04.

Pharmaceutical companies developing JAK family kinase inhibitors or therapies targeting inflammatory and autoimmune diseases should review this patent for freedom-to-operate considerations. Parties seeking to develop or commercialize TYK2 inhibitors for similar therapeutic applications may need to evaluate potential licensing or design-around options.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

TYK-2 inhibitor

Grant US12606556B2 Kind: B2 Apr 21, 2026

Assignee

BeOne Medicines I GmbH

Inventors

Qiuwen Wang, Yunhang Guo, Zhiwei Wang

Abstract

Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating disease associated with undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.

CPC Classifications

C07D 471/04

Filing Date

2021-02-25

Application No.

17801551

Claims

17

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Pharmaceutical IP Drug compound
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!